Qure's AMT-130 receives FDA Breakthrough Therapy designation for Huntington's disease, adding to Fast Track, RMAT, and Orphan ...

MTVA READ THE FULL MTVA RESEARCH REPORT Business Update Positive Phase 1 MAD Data for DA-1726 On April 15, 2025, MetaVia Inc.

Skye Bioscience currently trades essentially at cash value, meaning investors who buy in today get a weight loss drug ...

recently announced it has initiated its Phase I/IIa clinical trial at its first U.S. clinical site, the Johns Hopkins University School of Medicine. The first in human clinical trial will investigate ...

One of two of Opthea's phase III trials for a common eye disease has failed to meet its primary endpoints, ... Read More The post Health Check: Opthea’s solvency in question after monumental phase III ...

CERo Therapeutics (CERO) announces its first clinical trial site for the Company’s Phase 1 clinical trial of CER-1236. The trial is focused on ...

Glycomine’s Series C raise highlights investor confidence in the company amid pressure on the paediatric rare disease sector.

NeOnc Technologies (NTHI) announced that it expects full enrollment in its Phase 2a clinical trial for its lead therapeutic candidate, ...

Bicara Therapeutics shows potential to reshape cancer care with ficerafusp alfa and robust funding post-IPO. Find out why ...

Jonathan Kimmelman, PhD, has published multiple research papers and gotten into an inordinate number of debates about the clinical value of phase 1 trials.“I’ve argued for a long time that for phase 1 ...

Targeting first revenue in 2026, Recce will use new funds of up to $15.8m to support a Phase III registrational topical clinical trial for its diabetic foot infection (DFI) treatment in Indonesia.

Also supported will be the start of Phase III Acute Bacterial Skin and Skin Structure Infections (ABSSSI) registrational topical clinical trial in Australia. In a strong validation of the company ...